This series of files links two large population-based sources providing detailed data about Medicare beneficiaries with cancer. The SEER (Surveillance, Epidemiology, and End Results) program consists of clinical, demographic, and cause of death information collected from tumor registries beginning in January 1, 1973. The Medicare contribution includes all claims for covered health care services from beneficiaries’ time of eligibility until death. Linkage is processed biennially by SEER and Centers for Medicare and Medicaid Services (CMS) staff. 95% of individuals age 65 and older are included in the SEER files. Due to privacy concerns, access to this database requires an application, SEER-Medicare Data Use Agreement (DUA), and documentation of institutional review board approval. Additionally, the National Cancer Institute’s information technology contractor assesses a processing fee the amount of which is dependent upon the type and number of files requested.
The University of Michigan Health and Retirement Study (HRS) is a longitudinal panel study that surveys a representative sample of approximately 20,000 Americans over 50 years old. Core surveys take place every two years, with additional topics covered in off-year surveys. Data collected through a mix of phone and face-to-face interviews provides a comprehensive look at the changing experiences of older Americans on a range of topics including physical and mental health history and status, cognition, family structure, health care utilization and costs, financial status, and employment history and retirement plans. Interviews are supplemented with information from physical measurements, biomarker and genetic data, and linkages to administrative data.
This study investigated the association of age with CD4+ cell counts of HIV patients receiving antiretroviral treatment (ART) over a 4 year period. Data were collected from 126,672 previously treatment-naïve patients in 4 Sub-Saharan African nations. The baseline CD4+ count was measured at onset of ART and at 6-month intervals thereafter. The predictor variable was the age at initiation of therapy with ages grouped in five 10-year ranges: 20-29, 30-39, 40-49, 50-59, and 60 and over. The following 8 baseline covariates were also noted: sex, WHO stage, functional status, active TB infection, active cryptococcal disease, active P. jiroveci pneumonia, other active opportunistic infections, and ART regimen. The resulting dataset includes 466,482 repeated CD4+ count measurements with demographic and other patient-related characteristics.